Illumina's Q2 Array Revenues Rise on Whole-Genome Omni BeadChip Sales

CEO Jay Flatley said during the firm's second-quarter earnings call last week that Illumina has seen "encouraging uptake" of its Omni family of whole-genome arrays, which was the "largest component" of the company's microarray shipments during the quarter.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.